tradingkey.logo

Gri Bio Inc - IDMC Recommends Continuation Of Study With No Safety Concerns

ReutersApr 1, 2025 1:01 PM

- GRI Bio Inc GRI.O:

  • GRI BIO REPORTS ENCOURAGING INTERIM 2-WEEK SAFETY RESULTS FROM ONGOING PHASE 2A STUDY OF GRI-0621 IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”)

  • GRI BIO INC - IDMC RECOMMENDS CONTINUATION OF STUDY WITH NO SAFETY CONCERNS

  • GRI BIO INC - GRI-0621 SAFE AND WELL-TOLERATED IN FIRST 12 PATIENTS

  • GRI BIO INC - INTERIM BIOMARKER DATA EXPECTED Q2 2025, TOPLINE RESULTS Q3 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI